News & Trends - Biotechnology
Progressing the long-term plan for stem cell research
The Morrison Government is pleased to announce the next step in the $150 million Stem Cell Therapies Mission, with the release of the draft Roadmap for public consultation, which will help guide this 10-year investment in medical research.
The Mission is an opportunity for world-class Australian researchers to further investigate an area which presents significant opportunities for new medical treatments for many chronic and inherited diseases.
Australia is a global leader in stem cell science, with more 300 research laboratories focused on regenerative medicine and cell therapy.
Research advances over the last decade have shown the potential of stem cells to restore function to damaged tissues, engineer replacement tissues and organs and boost the body’s ability to heal itself.
Human stem cells can also be used in the lab to better understand what happens to the body during disease and to test new drugs without any risk to patients.
The Stem Cell Therapies Mission will support Australia’s talented researchers to further investigate what is possible through stem cell therapies.
The first grant opportunities under the Stem Cell Therapies Mission will begin in the coming months.
A Stem Cell Therapies Expert Advisory Panel has been selected to guide the Mission, and apply its experience and expertise to drafting the Roadmap.
The Morrison Government is funding the mission through its $20 billion Medical Research Future Fund—the single largest boost in health and medical research funding in Australia’s history.
The MRFF supports our world-class Australian researchers to make discoveries, develop a global biotech industry and enable the implementation of significant changes in health care.
For more information on the roadmap, and to provide feedback, visit https://consultations.health.gov.au/health-economics-and-research-division/mrff-stem-cell-therapies-mission
You may also like Multi-cancer blood test expands data in over 20 disease types
News & Trends - Pharmaceuticals
Lilly’s drug cuts diabetes risk by 94%, so why is it still not on the PBS?
On World Diabetes Day (14 November), new data reveals that three years of treatment with a GIP/GLP-1 receptor agonist significantly […]
MoreNews & Trends - Biotechnology
Depaz Oration to celebrate an ‘enduring’ legacy in the biotech sector
AusBiotech announced the establishment of the Depaz Oration, an annual keynote event that will debut at the AusBiotech Conference in […]
MoreNews & Trends - Pharmaceuticals
Government calls for public input on genomic-led cancer care
The Australian Government has launched a public consultation on a draft policy framework aimed at enhancing genomics-informed cancer care nationwide. […]
MoreNews & Trends - MedTech & Diagnostics
Can the patient voice reduce low-value care? Australia’s first large-scale hospital initiative seeks answers
In an Australian-first, a not-for-profit private health insurer will ask hospital patients to rate not only their clinical care but […]
More